LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Heart Failure Patients’ Blood Glucose Levels Predict Mortality Risk

By LabMedica International staff writers
Posted on 18 Jan 2015
Image: Gross pathology of idiopathic cardiomyopathy. Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium at autopsy (Photo courtesy of Dr. Edwin P. Ewing, Jr.).
Image: Gross pathology of idiopathic cardiomyopathy. Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium at autopsy (Photo courtesy of Dr. Edwin P. Ewing, Jr.).
The prognostic implications of blood glucose on a wide range of outcomes including early mortality, hospitalizations, and incident diabetes diagnoses have not been fully elucidated in acute heart failure syndromes (AHFS).

People who arrive at hospital emergency departments with acute heart failure should have their blood sugar levels checked on arrival as this simple and inexpensive measure could identify patients at high risk of early death, further hospitalizations, or the development of more health problems, such as diabetes.

Clinical scientists at the Institute for Clinical Evaluative Sciences (Toronto, ON, Canada) performed a competing risk analysis for 30-day mortality, new diabetes diagnoses, and hospitalization outcomes in a population-based cohort of 16,524 AHFS patients presenting to the emergency department (ED) in Ontario (Canada) between 2004 and 2007. Presentation blood glucose concentrations were categorized as follows: 3.9–6.1 (reference), >6.1–7.8, >7.8–9.4, >9.4–11.1, and >11.1 mmol/L.

The investigators found that patients without preexisting diabetes had a risk of death within 30 days from any cause that was 26% higher than the reference group if their blood glucose levels were between 6.1–7.8 mmol/L, rising to 50% higher if their levels exceeded 11.1 mmol/L. Their risk of death from cardiovascular causes was 28% higher for levels between 6.1–7.8 mmol/L, rising to 64% higher for levels between 9.4–11.1 mmol/L. As their blood glucose levels rose, so did their risk of subsequently developing diabetes; for levels between 6.1–7.8 mmol/L, their risk of diabetes was 61% higher, and this rose by 14% for every 1 mmol/L increase in blood glucose. If their levels exceeded 11.1 mmol/L, their risk of diabetes was 261% higher. Among all patients, with and without preexisting diabetes, blood sugar levels above 9.4 mmol/L increased the risks of hospitalization by 9%–15% for heart failure or cardiovascular causes.

Douglas S. Lee, MD, PhD, an Associate Professor of Medicine, and lead author of the study, said, “Our findings suggest that the measurement of blood sugar levels in all patients arriving at emergency departments with acute heart failure could provide doctors with useful prognostic information and could help to improve outcomes in these patients. It is a rapid, readily available and inexpensive test that could be used to enable doctors to quickly assess a patient’s risk for a wide range of possible outcomes and to suggest appropriate screening strategies that should be put in place.” The study was published on January 7, 2015, in the European Heart Journal.

Related Links:

Institute for Clinical Evaluative Sciences 


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more